# Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study

> **NCT07287137** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Henry M. Jackson Foundation for the Advancement of Military Medicine** · enrollment: 54 (estimated)

## Conditions studied

- COVID -19
- COVID - 19
- COVID 19
- Influenza
- Respiratory Virus
- Respiratory Viruses
- Respiratory Virus Infection
- Respiratory Virus Infections

## Interventions

- **DRUG:** Pfizer-BioNTech mRNA COVID-19 vaccine
- **DRUG:** Novavax recombinant protein vaccine

## Key facts

- **NCT ID:** NCT07287137
- **Lead sponsor:** Henry M. Jackson Foundation for the Advancement of Military Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-11-12
- **Primary completion:** 2027-09
- **Final completion:** 2027-09
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2026-05-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07287137

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07287137, "Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07287137. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*